On August 25, 2023, Hubbard-Hall acquired the assets of BioConversion Technology (BCT), a respected supplier of biologics and related chemistries for wastewater treatment. Jeremy Morgan, previously a VP of technology at BCT, has joined Hubbard-Hall as the Product Manager for Biologics within the company’s AquaPure product line of wastewater specialties.
Jeremy is a graduate of Georgia Institute of Technology with a degree in chemical engineering and is frequent speaker at water technology conferences. He will report to Robin Deal, AquaPure Product Manager.
Bioconversion, formerly headquartered in Georgia, was founded in 2000 by Kathleen Renzi. As Renzi stated, “It has been a rewarding 30 plus years and as I retire, l am both happy and proud that Hubbard-Hall will carry BioConversion forward.”
BCT products are custom blends of specially selected bacterial strains for the metal finishing, food, pulp and paper and petrochemical markets. The bacteria work under aerobic and anerobic conditions with no caustics or acids as to not cause harm to pipes or wastewater equipment.
“The BCT line of products – combined with Jeremy’s expertise in biologics – round out our offerings to our industrial customer base,” said Hubbard-Hall CEO, Molly Kellogg. “Bioaugmentation in metal finishing wastewater treatment is becoming more common as limits continue to tighten around Phosphorus, FOG, and BOD.”
“We now have a broader line to help our customers and as always, the best technical team in the business.”